Boston Family Office LLC Buys 1,152 Shares of Zoetis Inc. $ZTS

Boston Family Office LLC grew its stake in Zoetis Inc. (NYSE:ZTS) by 3.5% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 34,415 shares of the company’s stock after buying an additional 1,152 shares during the quarter. Boston Family Office LLC’s holdings in Zoetis were worth $5,367,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Brighton Jones LLC raised its stake in shares of Zoetis by 180.4% in the 4th quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock valued at $754,000 after purchasing an additional 2,978 shares during the period. Jupiter Asset Management Ltd. bought a new position in shares of Zoetis during the first quarter worth about $2,278,000. PNC Financial Services Group Inc. grew its holdings in shares of Zoetis by 3.9% during the first quarter. PNC Financial Services Group Inc. now owns 275,167 shares of the company’s stock worth $45,306,000 after buying an additional 10,294 shares in the last quarter. Banco Santander S.A. raised its position in Zoetis by 18.1% in the 1st quarter. Banco Santander S.A. now owns 19,741 shares of the company’s stock valued at $3,250,000 after buying an additional 3,030 shares during the last quarter. Finally, Bank of Nova Scotia lifted its stake in Zoetis by 143.0% in the 1st quarter. Bank of Nova Scotia now owns 180,690 shares of the company’s stock valued at $29,749,000 after acquiring an additional 106,347 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Trading Up 0.4%

Shares of NYSE:ZTS opened at $128.18 on Monday. Zoetis Inc. has a 52-week low of $115.25 and a 52-week high of $181.85. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76. The company has a market capitalization of $56.49 billion, a P/E ratio of 22.06, a price-to-earnings-growth ratio of 2.31 and a beta of 0.90. The company has a 50-day simple moving average of $135.77 and a 200 day simple moving average of $148.97.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Tuesday, November 4th. The company reported $1.70 earnings per share for the quarter, topping analysts’ consensus estimates of $1.62 by $0.08. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The firm had revenue of $2.40 billion for the quarter, compared to the consensus estimate of $2.42 billion. During the same quarter in the previous year, the business earned $1.58 earnings per share. The business’s revenue was up .5% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Sell-side analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 2nd. Investors of record on Friday, October 31st will be paid a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a yield of 1.6%. The ex-dividend date is Friday, October 31st. Zoetis’s dividend payout ratio is 33.67%.

Wall Street Analyst Weigh In

ZTS has been the subject of several research reports. Morgan Stanley decreased their price target on shares of Zoetis from $211.00 to $175.00 and set an “overweight” rating for the company in a research note on Monday, November 10th. Argus restated a “buy” rating and set a $190.00 target price on shares of Zoetis in a report on Tuesday, September 9th. Piper Sandler lifted their price target on shares of Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a research note on Monday, August 11th. JPMorgan Chase & Co. cut their price target on shares of Zoetis from $230.00 to $200.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 5th. Finally, Stifel Nicolaus reduced their price objective on shares of Zoetis from $140.00 to $130.00 and set a “hold” rating for the company in a research note on Tuesday, November 18th. Six investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $178.89.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.